- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
- Interventions
- Vincristine Sulfate Liposome Injection plus rituximab
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoma, Lymphoblastic
- Interventions
- Etoposide, cytarabine, vincristine, dexamethasone, methotrexate, teniposide, PEG-asparaginase, mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine, L-asparaginase, erwinia asparaginase, chemotherapy, intrathecal chemotherapy, steroid therapy, Hematopoietic Stem Cell Transplant, Natural Killer (NK) Cell Transplant
- Drug · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
- Conditions
- Follicular Lymphoma
- Interventions
- Venetoclax, Bendamustine, Rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 17
- States / cities
- Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 12 more
- Conditions
- Non-Hodgkins Lymphoma, Hodgkin's Disease, Acute Lymphoblastic Leukemia
- Interventions
- Dexamethasone, Irinotecan, Vincristine
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
- Interventions
- Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2036
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
- Interventions
- Elimusertib (BAY1895344)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 14
- States / cities
- Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
- Interventions
- Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate
- Drug · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Lymphomas Non-Hodgkin's B-Cell
- Interventions
- ET190L1 ARTEMIS™ T cells
- Biological
- Lead sponsor
- Eureka Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Lymphoma, Non-Hodgkin's
- Interventions
- lenalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 20
- States / cities
- Muscle Shoals, Alabama • Scottsdale, Arizona • Fountain Valley, California + 17 more
- Conditions
- Non-Hodgkin's Lymphoma, Cancer
- Interventions
- Vincristine, VP-16, Rituximab, Dexamethasone, Levofloxacin
- Drug
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Lymphoma
- Interventions
- rituximab, Cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy, Yttrium-90 ibritumomab tiuxetan, Indium-111 ibritumomab tiuxetan
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2015
- U.S. locations
- 48
- States / cities
- Anchorage, Alaska • Burbank, California • Boise, Idaho + 33 more
- Conditions
- Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia
- Interventions
- HSC835
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Leukemia, Lymphoma, Myeloma
- Interventions
- Busulfan, Gemcitabine, Melphalan, Hematopoietic Cell Transplantation, Rituximab for Patients with B-Cell Malignancies, Palifermin
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate
- Biological
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Follicular Lymphoma, Lymphoma, Follicular
- Interventions
- Zevalin Therapeutic Regimen, R-CVP
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more
- Conditions
- Lymphoma, Follicular, Lymphoma, Small Lymphocytic
- Interventions
- autologous human tumor-derived HSPPC-96
- Drug
- Lead sponsor
- Agenus Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome), Mixed Phenotype Acute Leukemia, NHL - Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, ALL
- Interventions
- T-allo10
- Biological
- Lead sponsor
- Roncarolo, Maria Grazia, MD
- Other
- Eligibility
- 3 Years to 45 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Lymphoma, Non-Hodgkin, HIV Infections
- Interventions
- Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Sargramostim, Dexamethasone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1996
- U.S. locations
- 22
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 13 more
- Conditions
- Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Cutaneous Lymphoma, Lymphomas: Non-Hodgkin Diffuse Large B-Cell, Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell, Lymphomas: Non-Hodgkin Mantle Cell, Lymphomas: Non-Hodgkin Marginal Zone, Lymphomas: Non-Hodgkin Peripheral T-Cell, Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
- Interventions
- Rituximab, Epratuzumab
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- FLT-PET scan, FDG-PET scan
- Procedure
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease
- Interventions
- SB-743921
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 6
- States / cities
- Hackensack, New Jersey • New York, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Lymphoma
- Interventions
- rituximab, cytarabine, liposomal cytarabine, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Radiation
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Burlington, Vermont
- Conditions
- Hodgkin's Disease, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- T-cell Non-Hodgkin's Lymphoma
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Wichita, Kansas • Hackensack, New Jersey + 1 more